Biotech · Private company
Ichnos Sciences SA
Track this companyFree. Adds Ichnos Sciences SA to your Dealase workspace and tells you when its record changes.
Clinical trials71 recruiting or active
Pipeline programs16From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline16
- GBR 830Phase 2 · Atopic DermatitisClinicalTrials.gov · fetched Nov 12, 2026
- ISB 1302 250 ng/kgPhase 2 · Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- ISB 1302 325 ng/kgPhase 2 · Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- ISB 1302 325 ng/kg-D1;425 ng/kg -D8,D15,D22Phase 2 · Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- ISB 1302 325 ng/kg-D1;550 ng/kg -D8,D15,D22Phase 2 · Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- ISB 1302 325ng/kg D1;550 ng/kg D8;900 ng/kg D15,22Phase 2 · Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- ISB 1302 325ng/kgD1;550 ng/kg D8;700 ng/kgD15,22Phase 2 · Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- ISB 1442 SC injection at RP2DPhase 2 · Relapsed/Refractory Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
- ISB 1442 SC injection escalating dosesPhase 2 · Relapsed/Refractory Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
- ISB 830 - Part 1 Group 1Phase 2 · Moderate to Severe Atopic DermatitisClinicalTrials.gov · fetched Nov 12, 2026
- ISB 830 - Part 1 Group 2Phase 2 · Moderate to Severe Atopic DermatitisClinicalTrials.gov · fetched Nov 12, 2026
- ISB 830 - Part 1 Group 3Phase 2 · Moderate to Severe Atopic DermatitisClinicalTrials.gov · fetched Nov 12, 2026
- ISB 830 - Part 2 Group 5Phase 2 · Moderate to Severe Atopic DermatitisClinicalTrials.gov · fetched Nov 12, 2026
- CD3/HER2 bispecific monoclonal antibodyPhase 1 · HER2 Expressing Solid TumoursClinicalTrials.gov · fetched Nov 12, 2026
- ISB 1342Phase 1 · Relapsed/Refractory Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
- ISB 2001Phase 1 · Relapsed/Refractory Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials7
- Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)PHASE1 · RECRUITING · started Nov 1, 2023ClinicalTrials.gov NCT05862012 · fetched Nov 12, 2026
- Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple MyelomaPHASE1_PHASE2 · TERMINATED · started Sep 27, 2022ClinicalTrials.gov NCT05427812 · fetched Nov 12, 2026
- Study of ISB 1302 (CD3 Bispecific Ab) in HER2-positive Metastatic Breast CancerPHASE1_PHASE2 · TERMINATED · started Apr 8, 2020ClinicalTrials.gov NCT03983395 · fetched Nov 12, 2026
- Phase 2b Study to Evaluate the Efficacy and Safety of ISB 830 in Adults With Moderate to Severe Atopic DermatitisPHASE2 · COMPLETED · started May 31, 2018ClinicalTrials.gov NCT03568162 · fetched Nov 12, 2026
- Study of ISB 1342, a CD38/CD3 Bispecific Antibody, in Subjects With Previously Treated Multiple MyelomaPHASE1 · COMPLETED · started Oct 25, 2017ClinicalTrials.gov NCT03309111 · fetched Nov 12, 2026
- Phase 1 Study of Single Agent GBR 1302 in Subjects With HER2 Positive CancersPHASE1 · TERMINATED · started May 1, 2016ClinicalTrials.gov NCT02829372 · fetched Nov 12, 2026
- To Assess the Safety and Activity of GBR 830, Compared to Placebo, in Adults With Moderate-to-severe Atopic DermatitisPHASE2 · COMPLETED · started Mar 1, 2016ClinicalTrials.gov NCT02683928 · fetched Nov 12, 2026